Here’s How Novartis is Prioritising Ethical AI Throughout Its Value Chain

A recent Global Data analysis of artificial intelligence jobs, deals, patents, and company filing mentions between October 2020 and September 2021 has placed Novartis as one of the top AI performers in the pharmaceutical industry today.

“AI is helping Novartis increase patient access, improve customer experience, drive automation, provide predictive analytics and detect potential misconduct,” said the company in a press statement. “It also has the potential to be used to improve the speed and accuracy of diagnosis, treatment protocols, drug discovery, drug development, patient monitoring, and patient care, among other applications that will improve patients’ lives and optimize the healthcare ecosystem.”

Clearly with the proliferation of artificial intelligence and the vast quantities of data which naturally come with it there must be a commitment from brands operating the technology to behave responsibly with it. This is something Novartis has recently laid out in writing with eight key principles of responsible AI use.

• Empower humanity
• Hold ourselves accountable
• Mitigate bias
• Respect privacy
• Be transparent and explainable
• Assure safety and security by design
• Prioritize environmental sustainability
• Review, learn, and adapt

Through these principles, Novartis intends to leverage the maximum benefit from AI technology, while ensuring it avoids the many pitfalls which can occur as a result of its widespread use.